Global viral vector manufacturing market is expected to grow significantly over the forecast period. It is projected that the global viral vector manufacturing market is expected to register a CAGR Approx. 22.65% with an expected market value of USD 319 million during the forecast period of 2018–2023. Gene therapy is one of the preferred treatment options for most chronic diseases, involving insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6890
Numerous factors such as rise in number of clinical trials, increase in the number of gene therapy candidates, and growing necessity for an effective mode of disease treatment are expected to drive the growth of the market. Also, the characteristics of viral vectors such as ability to express therapeutic genes efficiently, and non-pathogenic nature fuels the growth of the market. Moreover, several companies involved in the development of viral agent-based products often seek support in terms of strategic collaborations and acquisitions with contract service providers to deliver a clinical grade product. This is mainly because of the limited availability and complexity of platform and technologies used for vector designing, production, packaging, and release testing. For example, in December 2017, Merck announced a commercial supply agreement to manufacture viral vectors for Bluebird Bio, Inc. for its use in potentially transformative gene therapies. This move will accentuate the life science business of Merck as a leading contract manufacturing organization and commercial provider of viral vectors for gene therapy.
However, high cost of gene therapies and possible mutagenesis may hamper the market growth during the assessment period.
Global Viral Vector Manufacturing Market – Segmentations
The MRFR analysis is segmented into five key dynamics for enhanced understanding.
By Type: Retroviral Vectors, Adeno-Associated Viral Vectors, and Adenoviral Vectors among others.
By Disease: Cancer, Genetic Disorders and Infectious Diseases among others.
By Application: Gene Therapy and Vaccinology among others.
By End-user : Pharmaceutical Companies, Biotechnology Companies, and Research Institutes, among others.
By Regions: Asia Pacific, North America, Europe, and the Rest-of-the-World.
Global Viral Vector Manufacturing Market - Regional Analysis
The North American Region heading with the growing prevalence of autoimmune and chronic diseases, accounts for the leading market for viral vector manufacturing, globally. Moreover, technological advancements in the manufacturing of these vectors is a key force driving the growth of this market.
Additionally, favorable reimbursement policies and the presence of well-developed healthcare infrastructure, and increasing geriatric population are some of the key driving forces contributing to the growth of the regional market.
The U.S., backed by a large number of patients suffering from Alzheimer’s and Parkinson's diseases, majorly contributes to an increase in the demand for viral vectors in the region. Moreover, factors such as the high healthcare expenditures alongside the availability of viruses required for the production of these vectors and technological expertise drive the growth of the regional market.
The European region, led by the well-established R&D sector accounts for the second-largest market for viral vector manufacturing. Besides, factors such as the availability of funds for research and increasing healthcare expenditures drive the regional market. Moreover, the increase in occurrences of chronic diseases has led to the rise in the market growth in the region. Also, the presence of a developed healthcare sector and the resurging economy in the region foster the growth of the viral vector manufacturing market in Europe.
The upcoming viral vector manufacturing market trends in the Asia Pacific region is emerging as a promising market owing to the huge patient population suffering from diseases such as Parkinson’s, Alzheimer’s, and ALS.
Moreover, continuously growing healthcare sector led by the rapid economic growth in the APAC that is increasing the per capita healthcare expenses is a dominant driving force behind the growth of the regional market. Recent economic data suggests that China along with Southeast Asia is expected to join the ranks of the deep-pocketed Asian economies such as Taiwan and Korea.
China, owing to the presence of a huge geriatric population leads the viral vector manufacturing market in the APAC. Whereas, India due to the vast population base, rapidly changing economy, and the increasing number of manufacturers of these vectors, accounts for the second largest market in the region.
Whereas, the Middle East & Africa (MEA)region has the least market share due to the lack of awareness and low healthcare expenditures. The viral vector manufacturing market in the MEA region will exhibit moderate growth during the corresponding period.
Global Viral Vector Manufacturing Market - Competitive Analysis
The structure of the viral vector manufacturing market is changing due to the acquisition of local manufactures by multinational companies. Due to the increasing competition in the market, multination companies are using the strategy of acquisition, which has increased the profit of the company as well as significantly reduced the competition.
Major Players:
Key players leading the global viral vector manufacturing market include Sanofi, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Merck KGaA, General Electric Company, uniQure N.V., Oxford BioMedica, Spark Therapeutics, Inc., FinVector Vision Therapies, Cobra Biologics, Brammer Bio, Cell and Gene Therapy Catapult, REGENXBIO Inc., and Kaneka Eurogentec S.A. among others.
Industry/Innovation/Related News:
February 04, 2019 ---- SIRION BIOTECH GmbH (Germany), a leading global company providing the most comprehensive viral vector production and customization services announced its expansion in North America, hosting a Bavarian-themed grand opening event at the Forsyth Institute, the US to meet and mingle with the Cambridge gene therapy scene.
During the event, SIRION also mentioned that Gene therapy has seen robust clinical advancement and Sirion is becoming a preferred partner in this growing sector.
January 28, 2019 ---- SIRION BIOTECH GmbH (Germany), a leading global company providing the most comprehensive viral vector production and customization services announced its partnership with Denali Therapeutics to support local gene therapy research and clinical development with viral vector contract manufacturing. The licensing agreement is about developing a new generation of adeno-associated virus (AAV) vectors.
This ground-breaking licensing agreement (collaboration) is expected to help Denali Therapeutics to increase the availability of protein therapeutics and to quickly enter clinical trials with safe, efficient, and scalable therapeutic candidates.
While, this partnership with Denali, will help Sirion to send its CNS-directed AAV-based gene therapies to the market in the fastest way possible, providing advanced treatment options to millions of patients, worldwide.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890
No comments:
Post a Comment